Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 9/20 | 0.42 |
| ▸ | PTGES | O14684 | 6/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877509 | 1.00 | BCHE (0.42) | BCHECETPPTGESBACE1 | |
| SCHEMBL19365259 | 0.71 | CYP3A4 (0.42) | BCHEBACE1 | |
| SCHEMBL14441166 | 0.70 | LMNA (0.46) | BCHEBACE1 | |
| SCHEMBL9841880 | 0.69 | TSHR (0.52) | PTGES | |
| SCHEMBL4156025 | 0.69 | LMNA (0.41) | BCHECETP | |
| SCHEMBL18025550 | 0.69 | SIRT2 (0.49) | BCHE | |
| SCHEMBL8186958 | 0.68 | SLC7A5 (0.56) | BCHEBACE1 | |
| SCHEMBL4881688 | 0.68 | BCHE (0.62) | BCHEBACE1 | |
| SCHEMBL4881679 | 0.68 | BCHE (0.62) | BCHEBACE1 | |
| SCHEMBL879176 | 0.68 | HDAC6 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | BCHE 44/4885CETP 1811/4885PTGES 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.